Marino Stram & Associates’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.48M | Buy |
13,846
+105
| +0.8% | +$22.6K | 0.56% | 29 |
|
|
2026
Q1 | $2.99M | Buy |
13,741
+143
| +1% | +$31.7K | 0.54% | 33 |
|
|
2025
Q4 | $3.11M | Sell |
13,598
-1,042
| -7% | -$237K | 0.56% | 29 |
|
|
2025
Q3 | $3.39M | Buy |
14,640
+1,108
| +8% | +$226K | 0.61% | 27 |
|
|
2025
Q2 | $2.51M | Buy |
13,532
+252
| +2% | +$46.8K | 0.51% | 34 |
|
|
2025
Q1 | $2.78M | Sell |
13,280
-149
| -1% | -$29K | 0.62% | 31 |
|
|
2024
Q4 | $2.39M | Sell |
13,429
-61
| -0.5% | -$11.2K | 0.53% | 34 |
|
|
2024
Q3 | $2.66M | Sell |
13,490
-97
| -0.7% | -$18.1K | 0.59% | 30 |
|
|
2024
Q2 | $2.33M | Buy |
13,587
+51
| +0.4% | +$8.45K | 0.57% | 33 |
|
|
2024
Q1 | $2.46M | Buy |
13,536
+357
| +3% | +$61.5K | 0.58% | 32 |
|
|
2023
Q4 | $2.04M | Buy |
13,179
+35
| +0.3% | +$5.1K | 0.53% | 32 |
|
|
2023
Q3 | $1.96M | Sell |
13,144
-85
| -0.6% | -$12.5K | 0.57% | 33 |
|
|
2023
Q2 | $1.78M | Sell |
13,229
-270
| -2% | -$39.6K | 0.5% | 34 |
|
|
2023
Q1 | $2.15M | Sell |
13,499
-166
| -1% | -$25.4K | 0.65% | 30 |
|
|
2022
Q4 | $2.21M | Buy |
13,665
+587
| +4% | +$90K | 0.7% | 26 |
|
|
2022
Q3 | $1.75M | Buy |
13,078
+135
| +1% | +$19.4K | 0.63% | 30 |
|
|
2022
Q2 | $1.98M | Buy |
12,943
+3
| +0% | +$458 | 0.69% | 28 |
|
|
2022
Q1 | $2.1M | Buy |
12,940
+222
| +2% | +$32.2K | 0.66% | 31 |
|
|
2021
Q4 | $1.72M | Buy |
12,718
+431
| +4% | +$50.9K | 0.53% | 34 |
|
|
2021
Q3 | $1.32M | Sell |
12,287
-4,160
| -25% | -$475K | 0.46% | 37 |
|
|
2021
Q2 | $1.85M | Buy |
16,447
+5,672
| +53% | +$639K | 0.48% | 58 |
|
|
2021
Q1 | $1.17M | Buy |
10,775
+696
| +7% | +$74.4K | 0.46% | 40 |
|
|
2020
Q4 | $1.08M | Buy |
10,079
+178
| +2% | +$17.1K | 0.48% | 39 |
|
|
2020
Q3 | $867K | Buy |
9,901
+794
| +9% | +$74.8K | 0.46% | 41 |
|
|
2020
Q2 | $894K | Buy |
9,107
+1,985
| +28% | +$175K | 0.53% | 39 |
|
|
2020
Q1 | $543K | Buy |
7,122
+1,162
| +19% | +$99K | 0.42% | 49 |
|
|
2019
Q4 | $528K | Buy |
5,960
+280
| +5% | +$23.2K | 0.35% | 50 |
|
|
2019
Q3 | $430K | Buy |
5,680
+5
| +0.1% | +$343 | 0.3% | 52 |
|
|
2019
Q2 | $413K | Buy |
5,675
+1,380
| +32% | +$108K | 0.3% | 52 |
|
|
2019
Q1 | $346K | Buy |
4,295
+503
| +13% | +$41.1K | 0.25% | 57 |
|
|
2018
Q4 | $380K | Buy |
3,792
+2
| +0.1% | +$176 | 0.33% | 50 |
|
|
2018
Q3 | $358K | Sell |
3,790
-134
| -3% | -$12.7K | 0.29% | 54 |
|
|
2018
Q2 | $364K | Sell |
3,924
-244
| -6% | -$23.8K | 0.32% | 53 |
|
|
2018
Q1 | $394K | Sell |
4,168
-20
| -0.5% | -$2.2K | 0.36% | 52 |
|
|
2017
Q4 | $405K | Buy |
+4,188
| New | +$395K | 0.37% | 50 |
|
Other funds holding ABBV
ECSS
ATO
Marino Stram & Associates's ABBV Position: Q2 2026 in Review
Marino Stram & Associates increased its AbbVie (ABBV) stake by 0.76% in Q2 2026, buying an estimated $22.6K and bringing the position to 13,846 shares worth $3.48M. The position accounts for 0.56% of the portfolio, ranked #29.
Marino Stram & Associates first reported a position in ABBV in Q4 2017 and has held it in 35 quarters since. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Marino Stram & Associates held 13,846 shares of AbbVie worth $3.48M as of Q2 2026.
- Marino Stram & Associates bought 105 AbbVie shares in Q2 2026, an estimated $22.6K.
- AbbVie made up 0.56% of Marino Stram & Associates's portfolio in Q2 2026, its #29 holding.
- Marino Stram & Associates first reported a position in AbbVie in Q4 2017 and has held it in 35 quarters since.
- 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Marino Stram & Associates's 13F filing for Q2 2026, filed 24 Jul 2026.